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1. Abstract 
Abstract (English): 
Idiopathic arterial hypertension (IPAH) is a seldom but rigorous disorder, which relates to 
arteriopathy, transformation and preferentially thickening of the medial vessel layer. 
Moreover, altered behavior in migration and proliferation as well as resistance to apoptosis 
has been observed in IPAH pericytes. The molecular mechanisms leading to the named 
physiological changes are still sparingly researched. To explore the possible cause of seen 
pathology, we extracted pericytes from IPAH- and healthy donor lung tissue and did a gene 
analysis using a microarray. The test showed that the expression of PDK-4, an enzyme 
involved in the regulation of glucose metabolism, was highly upregulated. We 
hypothesized that the observed behavioral changes in IPAH-pericytes were caused by an 
inhibited glucose shift into the mitochondria. Our further tests showed an increased 
membrane potential and lowered reactive-oxygen-species-levels in IPAH pericytes. These 
results could be explained by the observed PDK4-upregulation. Following investigation 
could target the regulation of PDK-4 and further provide new therapeutic approaches in 
PAH-treatment. 
 
Abstract (German): 
Idiopathische arterielle Pulmonale Hypertonie (IPAH) ist eine seltene doch drastisch 
verlaufende Erkrankung, welche mit Arteriopathien und Veränderungen – vornehmlich 
Verdickung der medialen Gefäßwand – einhergeht. Weiters wurden verändertes Verhalten 
der Proliferation und Migration sowie eine Resistenz gegenüber Apoptose beobachtet und 
beschrieben. Die zugrundeliegenden molekularen Mechanismen sind derzeit noch 
spärlich erforscht. Um die möglichen Ursachen der beobachteten Pathologien zu 
untersuchen, extrahierten wir Perizyten aus IPAH- und gesundem Spenderlungengewebe. 
In Folge wurde eine Genanalyse mittels Microarray durchgeführt. Es zeigte sich eine – im 
Vergleich zum Gesunden – deutlich erhöhte Expression von PDK-4, ein Enzym welches 
in die Regulation des Glucosemetabolismus involviert ist. Wir vermuten, dass die 
beobachteten Verhaltensänderungen in IPAH-Perizyten einer Inhibition des 
Glukosetransports in die Mitochondrien zugrunde liegt. Unsere weiteren Tests zeigten ein 
erhöhtes Membranpotential und einen verminderten Wert von reaktiven Sauerstoffspezien 
in IPAH-Perizyten. Zukünftige Untersuchungsziele könnten sich auf die Regulation von 
PDK-4 beziehen und in Folge neue Therapieoptionen und -ziele liefern. 
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2. Background 
2.1 Pulmonary Arterial Hypertension 
2.1.1 Definition 
“Pulmonary arterial hypertension has been defined as an increase in mean pulmonary 
arterial pressure (PAP) > 25mmHg at rest assessed by right heart catheterization.” 
(taken from Simonneau G. et al. 2016). 
 
 
Figure 1 – Definition of PAH [taken and modified from Galiè N. et al. 2016, Table 3 used with permission 
from Dr. Galiè]  
 
2.1.2 Pathophysiology and Pathomechanisms 
The pathology of pulmonary arterial hypertension was first characterized in the late 19th 
century by E. von Romberg (1891). During the autopsy of patients with unknown lung 
disease he found lesions in the pulmonary vasculature, which he later called “Sclerosis of 
pulmonary arteries”. After declaring sclerosis to be the cause of this particular lung 
disease, a variety of studies to explain the pathophysiology and pathomechanism were 
conducted. One of the first explanations was a raise in blood pressure in the lung 
 5 
 
circulation. It was suspected that an increase of pressure led to a remodeling of arteries 
and small vessels due to the fact that lung vasculature was construed to low pressure 
(Hornowski J. 1914, Posselt A. 1925). 
 
Figure 2 - Classification of PAH in 6 grades [taken from Heath D. et al. 1958, Table 1] 
 
Further investigations in animal models (rats) showed that a hypoxic environment led to a 
remodeling of small vessels and pulmonary hypertension in pulmonary circulation. The 
results were consistent with clinical and pathological changes observed in PAH patients 
and autopsy results of PAH patients (Bennet GA. Et al. 1934). 
On the basis of previous studies and histological findings first approaches to classify the 
pathology of PAH were made. Heath D. et al. (1958) invented a classification in 6 stages, 
based on histological changes in arteries and arterioles. These histological alterations 
covered hypertrophied arterioles and arteries, intimal reactions such as fibrosis, plexiform 
lesions, pulmonary hemosiderosis and, in the end stage, necrotizing arteritis. 
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Figure 3 - Macroscopic and microscopic comparison of PAH- and healthy tissue. Images A and PAH-1 were 
taken from PAH lung tissue and visualize the vessel-wall thickening (diameter 28,1μm) and lumen 
narrowing known as pathological causation. In contrast to Images B and WT-1 (taken from healthy lung 
tissue), where a significant decreased vessel-wall diameter and wider lumen is seen. 
[A – thankfully provided by the department for Pathology, University Hospital St. Pölten; B- taken from 
Video Library – University of Wisconsin School of Medicine and Public Health; PAH-1/WT-1 thankfully 
provided by the de Jesus Perez Lab, Stanford University. 
 
Morphological hallmarks for pulmonary arterial hypertension are plexiform lesions. 
Plexiform lesions are complex vascular alterations originating from remodeled pulmonary 
arteries and small vessels. They are characterized by endothelial cell proliferation and 
muscular hypertrophy - preferentially thickening of the medial vessel layer – resulting in 
increased lumen - constriction and elevating the pressure as a result (Pietra G.G. et al. 
1989, Tuder R.M. 2009, Jonigk D. et al 2011). 
Heightened stages of vascular endothelial growth factor (VEGF) are suspected as being 
one cause of vascular remodeling. Elevated levels of VEGF, hypoxia inducible factor 1α 
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(HIF α 1) (Tuder R.M. et al. 2001, Tuder R.M. et al. 2009) vasoconstrictive mediators such 
as endothelin and thromboxane have been shown (Christman B.W. et al. 1992; Montani 
D. et al. 2013). Furthermore, alterations in proliferation, migration and a higher resistance 
to physiological apoptosis have been demonstrated (Masri F.A. et al. 2007, Malefant S. et 
al. 2013). 
To explore the cause of vascular remodeling, overexpression of angiogenesis inducing 
factors and resistance to apoptosis, studies to investigate a possible genetic background 
were conducted. 
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Table 1 – Pulmonary Arterial Hypertension: Risk Factors 
[Taken and modified from Galiè et al. 2016, thankfully provided by Dr. Gerald Simonneau] 
1. Pulmonary arterial hypertension 
1.1 Idiopathic 
1.2 Heritable 
1.2.1 BMPR2 
1.2.2 Other mutations 
1.3 Drugs and toxin induced 
1.4 Associated with: 
1.4.1 Connective tissue disease 
1.4.2 HIV infection 
1.4.3 Portal hypertension 
1.4.4 Congenital heart diseases 
1.4.5 Schistosomiasis 
1′ Pulmonary veno-occlusive disease and/or pulmonary capillary hemangiomatosis 
1′ .1 Idiopathic 
1′. 2. Heritable 
1′ .2.1 EIF2AK4 mutation 
1′ .2.2 Other mutations 
1′ .3 Drugs, toxins and radiation induced 
1′ .4 Associated with: 
1′ .4.1 Connective tissue disease 
1′ .4.2 HIV infection 
1′′. Persistent pulmonary hypertension of the newborn 
2. Pulmonary hypertension due to left heart disease 
2.1 Left ventricular systolic dysfunction 
2.2 Left ventricular diastolic dysfunction 
2.3 Valvular disease 
2.4 Congenital/acquired left heart inflow/outflow tract obstruction and congenital cardiomyopathies 
3. Pulmonary hypertension due to lung diseases and/or hypoxia 
3.1 Chronic obstructive pulmonary disease 
3.2 Interstitial lung disease 
3.3 Other pulmonary diseases with mixed restrictive and obstructive pattern 
3.4 Sleep-disordered breathing 
3.5 Alveolar hypoventilation disorders 
3.6 Chronic exposure to high altitude 
3.7 Developmental lung diseases 
4. Chronic thromboembolic pulmonary hypertension (CTEPH) 
4.1 Chronic thromboembolic pulmonary hypertension 
4.2 Other pulmonary artery obstructions 
4.2.1 Angiosarcoma 
4.2.2 Other intravascular tumors 
4.2.3 Arteritis 
4.2.4 Congenital pulmonary arteries stenoses 
4.2.5 Parasites (Hydatidosis) 
5. Pulmonary hypertension with unclear multifactorial mechanisms 
5.1 Hematologic disorders: chronic hemolytic anemia, myeloproliferative disorders, splenectomy 
5.2 Systemic disorders: sarcoidosis, pulmonary histiocytosis, lymphangioleiomyomatosis, neurofibromatosis 
5.3 Metabolic disorders: glycogen storage disease, Gaucher disease, thyroid disorders 
5.4 Others: pulmonary tumoral thrombotic microangiopathy,, fibrosing mediastinitis, chronic renal failure 
(with/without dialysis), segmental pulmonary hypertension] 
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2.1.3 Symptoms 
Patients with pulmonary arterial hypertension often present with unspecific symptoms, 
therefore the diagnosis is often delayed, and patients are diagnosed in an advanced stage 
of the disease. First signs appear as breathlessness, fatigue, weakness, decrease in 
exercise capacity, dizziness or syncope. Symptoms can be presented mildly, so the 
diagnosing process may be slow making the final diagnosis often happens in progressed 
stages (Rich S. et al. 1987, Galiè N. et al. 2009, Montani D. et al. 2013).  
 
2.1.4 Diagnosis 
The physical signs of the disease vary and depend on the stage of the illness. The clinical 
inspection in early stages is mostly without pathological findings, in advanced stages it 
repeatedly shows jugular vein distension, peripheral edema, cool extremities, ascites and 
hepatomegaly. Auscultation in early stages usually is inconspicuous, nevertheless several 
pathologies such as a pan-systolic cardiac murmur of tricuspid regurgitation or a diastolic 
cardiac murmur of pulmonary insufficiency in later stages. Further diagnostic- and disease 
monitoring tools are electrocardiograms (ECG), chest-x-rays, echocardiographic imaging, 
right heart catheterization, 6-min-walk-distance and blood values (Rich S. et al. 1987, 
Montani D. et al. 2013). 
Definition and diagnostic criterion for pulmonary arterial hypertension: “Pulmonary 
hypertension (PH) is defined by a mean pulmonary artery pressure ≥ 25 mm Hg at rest, 
measured during right heart catheterization.” (taken from Hoeper M.M. et al. 2013). 
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Table 2 - New York Heart Association Functional Classification  
[taken and modified from AHA, 2017] 
NYHA-I Asymptomatic patient;  
no limitations of physical activity 
NYHA-II 
 
Slight limitation of physical activity;  
normal physical activity results in dyspnea, fatigue, palpitations; 
comfortable at rest; 
NYHA-III Distinct limitation of physical activity; 
Mild physical activity results in dyspnea, fatigue, palpitations; 
Comfortable at rest; 
NYHA-IV Unable to carry on any physical activity without discomfort; Symptoms 
persist at rest;  
Physical activity increases discomfort; 
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2.1.4.1 Electrocardiogram (ECG / EKG) 
The ECG frequently shows a right axis 
deviation, a positive Sokolov Index for right 
ventricular hypertrophy (R in V1 + S in V5 > 
1,05mV or R in V2 + S in V6 > 1,05mV) and due 
to the right atrial enlargement supraventricular 
arrhythmias in late stages. (Sokolov et al. 1949, 
Rich S. et al. 1987, Rich J.D. et al. 2013, Tonelli 
A. et al. 2014).  
Furthermore, a prolonged QTc interval 
(>440ms) and widespread QRS (>100ms) 
complex have been shown in ECGs of PAH 
patients (Rich J.D. et al. 2013).  
The comparison of ECGs taken at diagnosis 
point and close to death shows a progression 
of PR-interval-duration and QRS-duration 
(Tonelli A. et al. 2014). 
 
 
 
 
  
Figure 4 - Electrocardiogram  
A - Sinusrhythm, normal axis, PQ- / QRS- / and QTc Values 
within the normal range, no ST- abnormalities, no T-wave 
abnormalities 
B- Sinusrhythm, right axis deviation, prominent R wave in 
V1-3 and T wave inversions in V1-6 
C - Atrial fibrillation, enlarged QRS complexed (>120ms = 
complete RBBB, > 100ms = incomplete  RBBB), enlarged 
and slurred lateral S waves in I, aVL, V5-6 (ind]icating 
delayed RV depolarization) 
 
[thankfully provided by Prof. Dr. Vinicio de Jesus Perez] 
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2.1.4.2 Chest x-ray 
The initial chest x-ray at diagnosis point shows abnormalities in approximately 90% of 
patients. Radiological findings can appear as enlargement of central pulmonary arteries, 
loss of peripheral blood vessels and/or enlarged right heart cavities (atrium/ventricle) (Rich 
S. et al. 1987, Galiè N. et al. 2016, Asha M. et al. 2017). 
 
 
Figure 5 - Chest X-Ray in PAH 
a) Postero-anterior projection showing dilated pulmonary arteries (stars), cardiomegaly (horizontal line), 
and rapid tapering (pruning) of right pulmonary artery (arrow). In addition, there is a decrease in the 
pulmonary vasculature in the periphery of the lung (arrow). (taken and modified from Asha M. et al. 2017, 
Fig. 2, figure used with permission from Dr. Alaa Gauda and Dr. Tonelli). 
 (b) Lateral projection depicting a decrease in the retrosternal air space (arrow); (taken and modified from 
Asha M. et al. 2017, Fig. 2, figure used with permission from Dr. Alaa Gauda and Dr. Tonelli).  
(c) 27a, female, PA projection (standing); Bone structure is normal, no signs of fractures, mediastinum is 
slim and centered, no tracheal shift, no sign of pulmonary congestion, heart configuration normal, heart 
diameter is regular, pulmonary vessels extend to the periphery, no pneumothorax, recussus clear, no 
signs of infiltrates or effusions, diaphragmatic cupola definable; [thankfully provided by the department 
of radiology, university hospital St. Pölten, Austria] 
(d) Radiological Imaging of pericardial effusion in a thoracic CT scan  
[thankfully provided by the department of radiology, university hospital St. Pölten, Austria] 
 
2.1.4.3 Echocardiography 
Echocardiography is an excellent diagnostic method for visualizing the anatomy in 
cardiology. With the transthoracic echo (TTE) the size of the chambers of the heart can be 
measured, also the valve- and pump function and the ejection fraction. Further the aorta 
ascendens, the arcus aortae and pericardial effusion can be visualized. With the Doppler-
sonography the blood flow can be evaluated and possible valve stenosis insufficiencies as 
well as the pulmonary arterial pressure can be identified. 
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Especially in obese patients, the transesophageal echo (TEE) facilitates a clearer image 
of the heart. Also, alterations in the atrial auricles for instance blood clots or vegetations in 
endocarditis are detected easier. 
 
For evaluating the right ventricular function several parameters must be determined. The 
size, ejection fraction and pump function, as well as the myocardial performance index and 
the tricuspid annular systolic excursion must be assessed. The cardiac pump function and 
ejection fraction give information about contractility, the tricuspid annular systolic excursion 
correlates with right ventricular function and the myocardial performance index is a 
parameter regarding the cardiac function. 
 
Tricuspid annular systolic excursion (TAPSE) is regularly evaluated during cardiac 
echocardiography and correlates with right ventricular systolic function. Low values (< 
15mm) indicate a decreased right ventricular systolic function and show a poorer prognosis 
in PAH patients (Forfia P.R. et al. 2006, Rudski L.G. et al. 2010, Brunner N.W. et al. 2015, 
Haddad F. et al. 2016). 
 
 
Figure 6 - Trans-thoracic-echocardiography in PAH patients 
(A) septum hypertrophy: diameter 14mm 
(B) tricuspid valve diameter: 44mm 
(C) right atrium diameter: 48mm 
[Images thankfully provided by the department of cardiology, university hospital St. Pölten, Austria] 
 
The myocardial performance index is a parameter that combines systolic and diastolic 
values of the right ventricle and gives information about the function. Values above >0,40 
(pulsed Doppler method) or > 0,55 (tissue Doppler method) are seen as pathological, 
limitations are irregular heart rates (Rudski LG et al. 2010). 
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The echocardiography of PAH patients shows a variety of pathological findings: right atrial 
and ventricular enlargement, increase of ventricular mass, tricuspid valve regurgitation and 
septum deviation and hypokinesis (Rich J.D. et al. 2013). Functional tricuspid-valve 
regurgitation leads to increased systolic volume in the right atrium, and (if not treated) 
results in right atrial enlargement. Reduced right ventricular systolic function and an 
extended right atrium can be seen as a manifestation of high pressure. Further a diastolic 
septum deviation towards the left ventricle is a sign of elevated right heart pressure and 
volume overload due to decreased cardiac output (Raymond R.J. et al. 2002, Rich J.D. et 
al. 2013, Haddad F. et al. 2016). 
 
Table 3 - Echocardiography in PAH 
[Taken and redrawn from Galiè N. et al. 2016, Tbl. 8A; used with permission from Dr. Galiè] 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Doppler sonography is a tool to measure the pulmonary artery systolic pressure (PASP). 
During the investigation, the maximum tricuspid regurgitant jet velocity (TRV) is measured 
Echocardiographic probability of pulmonary hypertension in 
symptomatic patients with a suspicion of pulmonary hypertension 
Peak tricuspid 
regurgitation 
velocity (m/s) 
Presence of 
other echos 
‘PH signs’ 
Echocardiographic 
probability of PH 
≤2.8 or not 
measurable 
No Low 
≤2.8 or not 
measurable 
Yes Intermediate 
2.9–3.4 No Intermediate 
2.9–3.4 Yes High 
>3.4 Not required High 
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and following the PASP is calculated: PASP = (4 x [TRV]²) + RAP). Pulmonary 
hypertension is unlikely if the PASP is below 36mmHg, suspect above 40mmHg and likely 
if above 50mmHg (Chemla G. et al. 2004, Galiè N. et al. 2009, Amsallem M et al. 2016). 
However, the validity of calculated PASP is limited by the tricuspid regurgitant jet – a 
deficient jet value can lead to false PASP calculations or interpretations (Amsallem M et 
al. 2016).  
 
2.1.4.4 Right Heart Catheterization 
Table 4 – Pressure values 
[taken from Klinke et al. 2005] 
Anatomic location Physiological pressure values 
Central venous pressure (CVP) 8-10mmHg  
Right atrial pressure (RAP) 2-28mmHg 
Right ventricular pressure (RVP) Systolic: 15-30mmHg 
Diastolic: 3-8mmHg 
Pulmonary artery pressure (PAP) Systolic: 15-30mmHg 
Diastolic:4-12mmHg 
Pulmonary capillary wedge pressure (PCWP) 2-15mmHg 
Left ventricular pressure (LVP) Systolic: 80-140mmHg 
Diastolic:3-12mmHg 
 
In 1970 the cardiologists William Ganz and Jeremy Swan invented the Swan-Ganz-
Catheter, a catheter which is inserted percutaneously via the venous system into the right 
heart. The method is used to determine the pulmonary capillary wedge pressure (PCWP) 
- a balloon is inflated and wedged into a small arterial vessel (Swan H.J. et al. 1970). From 
the gained pressure values conclusions about the left-heart-function, blood volume and 
flow velocity or oxygen saturation can be drawn.  
An elevated PCW and PA pressure was described in several studies, focusing on PAH-
patients or -animal models (Rich S et al. 1987, Montani D. et al. 2013). 
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As mentioned before, PAH is defined as PAP > 22mmHg, PCWP ≤15mmHg and PVR >3 
Wood Units (Badesch D.B. et al. 2009, Hoeper M.M. et al. 2009, Galiè N. et al. 2016). 
 
Another very strong parameter in the diagnostic process of PAH is the cardiac output. The 
cardiac output per minute can be roughly calculated by multiplying the current heartrate 
with the stroke volume. However, the cardiac output per minute is influenced and 
determined by several variables such as anatomical conditions, pre- and afterload and 
contractility (Klinke et al. 2005). In addition to measure valid pressure values for the right 
heart, right heart catheterization gives clinicians also the possibility to estimate the 
patient’s cardiac output by evaluating pulmonary artery and pulmonary wedge pressure 
(Hoeper M.M. et al. 2009, Galiè N. et al. 2016). By using thermodilution, a bolus of e.g. 
sterile ice-cold saline is injected via the catheter in the right atrium. Father distal a thermo-
sensor integrated in the catheter measures the drop of temperature. The measured time 
delay is used to calculate the ejection fraction and cardiac output (Hoeper M.M. et al. 1999 
and 2009, Galiè N. et al. 2016). Also, the cardiac output can be calculated by using the 
direct Fick-method: “..as the quotient of oxygen uptake (VO2) and the difference of the 
arterial and mixed venous oxygen content.” (taken from Hoeper M.M. et al. 1999). 
To evaluate the oximetry, Galiè N. et al. 2016 recommended to take (blood) samples from 
vena cava superior and inferior as well as samples of the pulmonary artery. Further they 
suggested a stepwise evaluation of PAH patient’s oxygen saturation. 
In addition to evaluating pressure levels and taking blood samples to determine oxygen 
saturation values, testing vasoreactivity is recommended for patients belonging to group 1 
PAH. The test is administered via giving intravenous epoprostenol or nitric oxide and 
considered as positive, if a drop of minimum 10mmHg and reaching a pulmonary artery 
pressure equal or lower than 40mmHg without a worsening of cardiac output is registered. 
Positive testing prognosticates better survival and effect of calcium channel blocker 
therapy (Tonelli A.R. et al. 2009, Goldberg A.B. et al. 2017). 
 
2.1.4.5 6-Minute-Walk-Distance (6MWD) 
By measuring the 6-min-walk-distance, the patient's’ exercise capacity and 
symptomatology under physical stress in measured. In 2002 in an official statement the 
American Thoracic society showed, that the 6MWD of healthy adults was >500m in 
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average. PAH patients in NYHA-stages II-IV usually have lower testing values. Raymond 
R.J. et al. 2002 and Wensel R. et al. 2002 showed, that the results of the 6-min-walk-test 
directly correlate with the outcome. A high value (>380m) is a positive prognostic criterion, 
patients with a decreased 6-min-walk-distance are more likely having a worse outcome.  
Nevertheless the 6-minute-walk-distance is a test that is influenced by a variety of extrinsic 
factors such as age, gender, general physical condition and previous diseases especially 
to the musculoskeletal-system. Further mental aspects such as compliance and motivation 
can also limit the 6MWD. The test value is given in absolute numbers, which limits the 
potential to individualize scores to the patient and show improvement or deterioration over 
time and therapy (Sitbon O. et al. 2002, Benza RL. et al. 2010, Grünig E. et al. 2012, Demir 
R. et al. 2014, Galiè N. et al. 2016). 
 
Table 5 - 6-Min-Walk-Distance  
[Taken from Badesch D.B. et al. 2010] 
NYHA-I 475.5 ± 9.3m 
NYHA-II 419.2 ± 3.7m 
NYHA-III 323.1 ± 3.8m 
NYHA-IV 214 ±13.7m 
 
2.1.5 Therapy 
Thanks to intensive research and development novelties in pharmaceuticals the therapy 
options for pulmonary arterial hypertension patients have increased. Nowadays PAH 
treatment is a multimodal concept which combines specific pharmacotherapy with 
supportive therapy – for example the use of diuretics and/or oxygen – and general 
measures such as physical therapy, rehabilitation, infection prevention, birth control and 
psychosocial support. 
The available therapeutics target the main vasoconstrictive pathways: the prostacyclin 
pathway and the endothelin-pathway. In addition, PAH therapy addresses 
phosphodiesterase-V levels and influences the vessel-tone via calcium-channel-blockers 
(Venteluolo C.E. et al. 2012, Seferian A. et al. 2013).  
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Figure 7 - Evidence based treatment algorithm for pulmonary arterial hypertension patients - for group 1 
patients only.  
[Taken and redrawn from Galie N. et al. 2015, Fig. 2, figure used with permission from Dr. Galiè] 
 
2.1.5.1 Prostacyclin pathway 
The enzyme cyclooxygenase transforms arachidonic acid to prostaglandin PGH2, which 
is metabolized via prostacyclin synthase to the transmitter prostacyclin. By binding to the 
prostacyclin receptor, the transmitter activates a G-protein coupled pathway and enhances 
the intracellular cAMP levels. As a consequence of the second messenger elevation, 
vasoconstriction decreases and so does the blood pressure. Furthermore, prostacyclin 
inhibits the platelet aggregation and has an antiproliferative effect. 
The medication can be applied intravenously (Epoprostenol), subcutaneously (Teprostinil) 
and by inhalation (Teprostinil, Iloprost) and orally (Selexipag). 
Epoprostenol treatment is administered via a permanently implanted venous access 
system (e.g. a central venous catheter) via using a portable pump. The initial dosage is 1 
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to 2 ng/kg per min and is increased continuously, based on the patient's tolerance. Barst 
R.J. et al. showed in 1996 in a prospective, randomized, multicenter open trial the 
effectiveness of continuous epoprostenol infusion compared to conventional therapy. 
Patients presented an improvement in physical resilience and a depletion in mean PAP 
and PVR. 
Side effects are documented and include arthralgia, jaw pain and flush. In addition, 
clinicians should keep the side effects caused by the implanted catheter such as infection, 
thrombosis or pump malfunction in mind (Barst R.J. et al. 1996, Rich S: et al. 1999, Oudiz 
R.J. et al. 2004, Galiè N. et al. 2016). 
 
Treprostinil - a prostacyclin analog - can be administered subcutaneously via a micro-
infusion pump or a subcutaneous catheter (Galiè N. et al. 2016). The initial dosage is 1 to 
2 ng/kg per min, however an increase in dosage is limited by severe pain in the area of 
injection or the placed subcutaneous catheter as well as other side effects such as flush 
and headaches (Simonneau G. et al. 2002, Galiè N. et al. 2016). The substances half-
value period is longer compared to epoprostenol, following a catheter blockage or a 
dislocated catheter is not as life threatening and – according to the data - a transition from 
epoprostenol to treprostinil is possible and efficacious (Gomberg-Maitland M. et al. 2005). 
Simonneau G. and his group presented a randomized controlled trial in 2002, showing an 
advancement in physical fitness, a refinement in hemodynamics as well as a reduction of 
symptoms, such as dyspnea. 
 
The synthetic analog iloprost can be applied orally, per inhalation or intravenously. 
Inhalation of Iloprost showed an advancement in 6MWD and in addition an enhancement 
in hemodynamic parameters and symptoms such as dyspnea and following in the NYHA 
class (Olschewski H. et al. 2002, Galiè N. et al. 2016). Yet due to the high frequency of 
inhalations – app. six to nine times per day – the practicability of this treatment method is 
disputable. 
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Selexipag belongs to the group of non -prostanoid prostacyclin receptor agonists and is 
orally administered. It reduces the pulmonary vascular resistance and the systemic 
vascular resistance and increases the cardiac index (Simonneau et al. 2012). 
Sitbon O. and his team published a large randomized, placebo-controlled study in 2015 
with 1156 PAH WHO-Group 1 participants. The selexipag dosages were individually 
aligned with a maximum of 1600µg two times per day. The study did not show a significant 
discrepancy in mortality comparing the two groups, however it showed a decrease in 
disease progression and hospitalizations for disease aggravation. 
 
2.1.5.2 Endothelin pathway 
The substance endothelin belongs to the class of peptide hormones and is produced in 
the endothelium of blood vessels. The hormone acts via a G-protein-coupled pathway and 
induces local vasoconstriction, therefore it increases the intravascular pressure. Moreover, 
it provokes cellular proliferation and remodeling and is conductive to cardiac hypertrophy. 
Three subtypes are known so far, Endothelin-1 -2 and 3-, ET-1 is the most potent 
vasoconstrictor. 
The synthetic endothelin-receptor-antagonists (ERA) bosentan, macitentan and 
ambrisentan unfold their effect via inhibiting the binding of endothelin to the receptor. 
Therefore, the reaction cascade can’t take place and the vascular tone decreases. 
Common side effects are hypotension, increase in transaminases, headache, edema and 
pruritus. (Hoeper MM et al. 2005, Herold G et al. 2011, Venteluolo CE 2012). 
 
Bosentan belongs to the group of oral non-selective endothelin receptor antagonists. 
Rubin L.J. et al. issued a double-blind, placebo-controlled study in 2002 where patients 
were treated with either a placebo or 62.5mg bosentan twice a day for four weeks. After 
that, the treatment continued with an ongoing treatment with 125 or 250mg twice daily for 
an additional twelve weeks. The study demonstrated amelioration of physical capacity, 
dyspnea and following functional class. In 2008, Galiè N. et al. also found several 
differences between the bosentan group compared to the placebo reagent group. The 
research team demonstrated improvement of physical capacity (measured by the 6MWD), 
as well as a lowered pulmonary vascular resistance.  
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Also, the reagent macitentan belongs to the group of oral non-selective endothelin receptor 
antagonists. Pulido T. et al. released in 2013 the SERAFIN trial. The study included 
patients with moderate to severe PAH-group 1 patients. They received either 3mg or 10mg 
macitentan once a day over two years. The findings demonstrated a decelerated disease 
progression and further an enhancement of physical capacity. The effectiveness of 
macitentan treatment was proven regardless of additional PAH treatment. 
 
Ambrisentan belongs to the oral selective endothelin-1-receptor type A antagonists. Galiè 
N. et al. published a double-blind study in 2005 about the effects of orally administered 
ambrisentan for twelve weeks (doses were 1, 2.5, 5 or 10mg given once a day). The patient 
cohort incorporated patients with idiopathic PAH, PAH associated with collagen vascular 
disease, anorexigen use or HIV infection. Results showed a substantial elevation of 6-min-
walk-distance, as well as a decrease in mean pulmonary artery pressure and cardiac 
index. 
 
2.1.5.3 Phosphodiesterase-V-Inhibitors 
Phosphodiesterase-V-inhibitors prohibit the effect of the enzyme Phosphodiesterase-V on 
the cGMP pathway. The second messenger cGMP (cyclic Guanosin-Monophosphate) 
activates intracellular protein kinases and induces vasodilation in vascular smooth muscle 
cells in its wake. The PDE-V-inhibitors Sildenafil and Tadalafil are approved drugs for 
mono- and combination therapy of pulmonary arterial hypertension. Common side effects 
are headaches, hypotension, dizziness and priapism. (Herold G et al. 2011, Venteluolo CE 
2012, Herold G et al. 2011, Galiè N. et al.  2016). 
 
Sildenafil is a powerful suppressor of phosphodiesterase-5, orally administered. Galie N. 
et al. published a double-blind, placebo-controlled study about the effects of Sildenafil 
given to systematic pulmonary arterial hypertension patients in 2005. The substance-
receiving-group was treated with sildenafil orally, three times a day for twelve weeks (either 
20, 40 or 80mg). The sildenafil-group demonstrated an enhancement of exercise capacity 
 22 
 
(improvement of 6-min-walk-test), a decline in mean PAP and a revision of functional class. 
Similar results were seen in a later published randomized controlled study assessing the 
efficiency of orally administered sildenafil (Singh T. et al. 2010). 
 
Tadalafil is also an orally administered phosphodiesterase-5-inhibitor, but in contrast to 
sildenafil given only once a day. Galiè N. et al. published a double-blind, placebo-controlled 
study evaluating the impact of tadalafil in 2009. Given the maximum of 40mg tadalafil once 
a day, the patients showed an improvement in 6-min-walk-distance, an enhancement in 
time to clinical worsening and better quality of life. Side effects such as headache, myalgia 
and flush were reported. 
 
Riociguat is a novel therapeutic agent, that belongs to the soluble guanylate cyclase (sGC) 
stimulators. By stimulating the sGC the synthesis of cyclic guanosine monophosphate is 
triggered and following as vascular vasodilation is achieved. In addition to its direct 
stimulation, riociguat also increases the body’s own sensitivity for endogenous nitric oxide 
(Grimminger F. et al. 2009). Ghofrani H.A: et al. published a study in 2013 with 443 
assigned patients. The maximum dose of riociguat was 2.5mg given three times a day 
orally. The participants showed substantial ameliorated exercise capacity, and 
enhancements in PVR. 
  
2.1.5.4 Calcium-channel-blockers  
Calcium-channel-blockers are therapeutic reagents which inhibit the signal-transduction in 
L-type calcium-channels by binding to the receptor. The decreased intracellular calcium-
level causes a vasodilation in the vasculature. In the myocardium, the reduced calcium 
level results in decreased inotropy, chronotropy and blood pressure as well as the oxygen 
consumption sinks. 
Calcium-channel-blockers have a large therapeutic margin and the application spectrum 
ranges from migraine prevention to coronary heart disease, arterial hypertension, Morbus 
Raynaud and Prinzmetall-Angina to pulmonary hypertension. 
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Side effects may be edema, hypotension, dizziness, headaches and flush- or tachycardia. 
(Herold G. et al. 2011, Herold G. et al. 2011, Venteluolo C.E. 2012). 
Depending on the patient's’ heart rate, different substances are available. Patients who 
tend to bradycardia favor amlodipine and nifedipine, tachycardia patients favor diltiazem. 
The effective dose rate is relatively high compared to other indications for calcium channel 
blockers. 
Starting with lower dose rates, the increase of dosage goes up to a maximum of 20mg for 
amlodipine, 240mg for nifedipine and 720 mg for diltiazem (Galiè N. et al. 2016). 
However, the indication for calcium-channel-blocker therapy in pulmonary arterial 
hypertension is limited and only for patients with a positive vasoreactivity (Galiè N. et al. 
1995, Galiè N. et al. 2016). Further, patients who receive treatment with calcium channel 
blockers should be observed and monitored strictly and undergo a follow up examination 
approximately three to four months after starting the treatment, including another right 
heart catheter assessment (Galiè N. 2016). Properly managed and given to a patient with 
vasoreactivity, a therapy with this substance group can decrease the mean pulmonary 
arterial pressure and the pulmonary vascular resistance (Sitbon O. et al. 2005). 
 
2.1.5.5 Combination therapy and additional measurements 
The combination of two or more PAH-specific therapeutics is recommended if the patients 
response to a single drug treatment is poor or no improvement has been shown at all. If 
adjusted adequately, combination therapy is well tolerated. (Hoeper MM et al. 2005, Galiè 
N et al. 2013, Montani D et al. 2014, Venteluolo CE 2012, Müller-Mottet S et al. 2015). 
In 2016, Sitbon O. and his team published a retrospective analysis, demonstrating a 
therapeutic approach using initial dual oral combination. The majority (in total 61) received 
a treatment combination of bosentan plus sildenafil, 17 patients were treated with bosentan 
plus tadalafil,11 patients were treated with a combination of ambrisentan plus tadalafil and 
8 patients received a combination of ambrisentan plus sildenafil. The study participants 
were initially assessed 4 months after start of dual oral treatment. According to the authors, 
the patients showed significant improvements in physical shape and exercise capacity, 
symptoms such as dyspnea, WHO functional class and hemodynamic parameters 
(reduction of pulmonary vascular resistance). The median follow-period was 30 months 
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and the results supported the initial findings. In summary the research presented, that first 
line oral dual therapy (endothelin receptor antagonist plus Phosphodiesterase-V-Inhibitor) 
increases exercise capacity, cardiac index and on the other hand decreases right atrial 
pressure and pulmonary vascular resistance (e.g. a reduction of pulmonary vascular 
resistance of 40-50% in dual therapy compared to a reduction of 30% in monotherapy).  
Furthermore, infection prevention, birth control and the choice of anesthesia in elective 
surgery can influence the progress of the disease. Although efforts were made to find a 
proper treatment algorithm, the options are still limited, and the treatment plan is oriented 
at individual response, medical preconditions and drug interactions (Galiè N. et al. 2016). 
Summarizing, only the symptoms but not the origin of the disease can be treated. It is still 
a progressive and fatal disease and the only known cure so far is lung or combined heart-
lung-transplant.  
 
2.1.6 Prognosis 
During the past years approaches to find new treatment options and algorithms were 
made. The response to new therapeutic reagents and the reduction of side effects 
increased the livability and therapeutic management. Prognosis and survival of PAH 
patients are still limited and correlates with the NYHA-stage at diagnosis point, the 
response to pharmacotherapy, lifestyle changes and supportive therapy such as infection 
prevention, birth control and psychosocial support. 
In 1991 D'Alonzo A. et al. described the median survival time for PAH in correlation to the 
NYHA stage as following: “NYHA I + II: 58,6 months, NYHA III: 31,5 months, NYHA IV: 6 
months”. The mortality is correlated with right ventricular hemodynamic function, 
pulmonary artery pressure and right arterial pressure as well as with the cardiac index. 
In 2002 McLaughlin V.V. described the survival of PAH patients with epoprostenol 
treatment subsequently: “1-year survival: 88%, 2-year survival: 76%, 3-year survival: 
63%”. 
In 2002 Sitbon O. et al. also investigated the survival of PAH patients with epoprostenol 
treatment: “1-year survival: 85%, 2-year survival: 70%, 3-year survival: 60%”. 
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Benza R.L. et al. published a study in 2010 evaluating the causal variables of one-year-
survival in PAH patients. The study included 2716 patient who previously registered in the 
US Registry to evaluate Early and Long-Term PAH Disease management (REVEAL). The 
investigators determined five risk groups. Patients with low risk belonged to the IPAH 
subgroup, were demographically 35 y/o females. Renal insufficiency was an optional 
comorbidity, the vital parameters showed a regular heart rate and normotensive blood 
pressure values. In cardiac echo no pericardial effusion was seen, the mRAP was app. 
8mmHg and exercise capacity was around 360 (6-MWD). In contrast to these values, the 
group with very high risk belonged to the Scleroderma-subgroup, the patients were 
generally 55y/o females with renal insufficiency, pericardial effusion seen in 
echocardiogram, increased mRAP (app. 22mmHg) and decreased exercised capacity 
(app. 200m in 6-MWD). Further the authors stated that “..only an elevated mean right atrial 
pressure within the year preceding study enrollment and a markedly increased pulmonary 
vascular resistance were independent risk predictors.” (taken from Benza R.L. et al. 2010). 
 
The survival numbers of PAH patients have increased, and their prognosis has improved 
over the years compared to earlier periods (Müller-Mottet S. et al. 2015), nevertheless 
treatment options are still limited. 
 
Figure 8 - Prognosis and Survival in PAH 
(A) Kaplan-Meier estimates of 1-year survival from time of enrollment. Dashed lines represent the 95% CI 
for the Kaplan-Meier estimates. 
(B) Observed 1-year survival from time of enrollment according to predicted risk strata. 
[Taken from Benza R.L. et al. 2010 A=Fig. 1 and B=Fig.2, figures used with permission from Dr. Benza] 
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2.2 The Connection between PAH and Pericytes 
Besides finding new treatment options for IPAH patients, the focus of research has turned 
to the initial cause and origin of cellular changes in small- and micro vessels. 
Alteration in migration, proliferation and apoptotic behavior has been observed (Malefant 
S. et al. 2013), and with these new findings, not only vascular muscle cells and endothelial 
cells, but also pericytes have been brought into focus. Pericytes originate from 
mesenchymal stem cells (Shakib et al. 1966; Díaz-Flores L. et al. 2009) and are mostly 
found in the layer of non-muscular microvessels and capillaries (Weibel E.R. et al. 1974). 
Pericytes envelope lumen-building endothelial cells (Weibel E.R. et al. 1974), evolve cell 
junctions (gap junctions) and are suspected to influence angiogenesis, differentiation and 
multiplication of endothelial cells by expressing cytokines such as TGFbeta-1 or PDGFR-
beta-1 (Song S. et al. 2005, v. Tell D. et al. 2006, Díaz-Flores L. et al. 2009) and other 
vasoactive substances (Peppiat C.M. et al. 2006). 
Pericytes dysfunctions or mutations lead to vessel wall instability (Weibel E.R. et al. 1974; 
v. Tell D. et al. 2006) and increased endothelial membrane permeability (Bell R.D. et al. 
2010). Pericytes maintain their plasticity for differentiation into other cell types like 
endothelial or smooth muscle cells. Prospectively causing higher amounts of proliferating 
cells in IPAH vessels, which constrict the lumen and finally raise the resistance and 
pressure (Lee S.D. et al. 1998). 
 
2.3 Vascular Alterations and Enhancement of 
Angiogenesis 
As previously written on, the first description of pulmonary arterial hypertension was done 
by E. von Romberg in 1891, who characterized the alterations in lung vasculature found in 
the autopsy of his patients as sclerosis. Ever since, a variety of studies was published 
whose authors tried to understand the histological changes observed in patients with so 
called “arteriosclerosis pulmonalis” (Hornowski J. 1914, Posselt A. 1925). Thanks to the 
new awareness in physiology and pathology as well as development of new technologies, 
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the focus of research turned from histologic findings to investigations in biochemical 
background. 
The disease is also associated with so called plexiform lesions. These lesions are 
characterized by an overexpression of the vascular endothelial growth factor (VEGF) by 
endothelial cells as well as additional angiogenesis influencing factors (Geraci M.W. et al. 
2001; Tuder R.M. 2009). Furthermore, heightened expression of VEGF and hypoxia 
inducible factor 1α (HIF α 1) (Tuder R.M. et al. 2001) as well as vasoconstrictive mediators 
such as endothelin and thromboxane and muscularization of arterioles and capillaries have 
been shown (Christman B.W. et al. 1992; Montani D. et al. 2013). The development of 
IPAH due to mutations in the bone morphogenetic protein pathway (BMP-pathway) and 
the coding gene for bone morphogenetic protein receptor type 2 (BMPR2) has been 
proven (Deng Z. et al. 2000; Morrell N.W. 2006). 
Intensified angiogenesis and overexpression of angiogenesis stimulating and influencing 
factors are believed to be the cause of vascular remodeling and following causing the 
microscopically and macroscopically observed alterations. 
As mentioned above, pericytes originate from mesenchymal stem cells (Shakib et al. 1966; 
Díaz-Flores L. et al. 2009), keep their ability to differentiate into other cell types (Lee S.D. 
et al. 1998) and envelope lumen-building endothelial cells (Weibel E.R. et al. 1974). Due 
to these realizations, the focus of research turned towards pericytes and their potential 
involvement in lumen-narrowing and pressure elevating processes in idiopathic pulmonary 
arterial hypertension (Lee S.D. et al. 1998). 
 
2.4 Pericytes 
The history of pericytes date back to the late 19th century and was first described in 1871 
by the scientists C.J. Eberth and in 1873 by C. Rouget as “..population of contractile cells 
surrounding the endothelial cells of small blood vessels (Rouget, 1873).” (taken from 
Armulik A. et al. 2011). In the 1920s K.W. Zimmermann described so called “Rouget-cells” 
(later pericytes) and their anatomic location in his scientific paper “Der feine Bau der 
Blutcapillaren”. 
Pericytes originate from mesenchymal stem cells (Shakib et al. 1966; Díaz-Flores L. et al. 
2009) and are primarily found in the layer of non-muscular microvessels and capillaries 
(Weibel E.R. et al. 1974). In addition, they enclose lumen-building endothelial cells (Weibel 
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E.R. et a. 1974) and develop cell-connections such as gap-junctions. By expressing 
mediators and messengers such as TGF-beta-1 or PDGFR-beta-1 or other partial vaso-
active substances, they are suspected to affect and/or manipulate differentiation and 
multiplication of endothelial cells and angiogenesis (Díaz-Flores L. et al. 2009, Peppiat 
C.M. et al. 2006, v. Tell D. et al. 2006). Moreover, pericytes retain their ductility to 
differentiate into other cell lines such as endothelial- or smooth muscle cells. 
Suspicion is entertained that pericytes dysfunction or mutation induce vessel-wall 
instability (Weibel E.R. et al. 1974; v. Tell D. et al. 2006) and increased endothelial 
membrane permeability (Bell R.D. et al. 2010). Also altered behavior in proliferation, 
migration and apoptosis has been found (Malefant S. et al. 2013). An increased level of 
proliferation for example in IPAH lung vasculature leads to vessel-wall-thickening and 
therefore lumen-constriction which following leads to an increased vessel-wall-resistance 
and elevated intravascular pressure (Lee S.D. et al. 1998). 
The new knowledge of pericytes-function and altered behavior in diseases puts this cell 
type in the focus of research. 
 
2.5 Mitochondria 
2.5.1 Overview 
The mitochondrion is very often characterized as the power station of the cell – it contains 
a large variety of metabolic pathways, processes metabolites and in the end, generates 
ATP. The number of mitochondria in a cell is dependent on the metabolic activity of the 
particular tissue, the amount can be increased by training for example in skeletal- and 
heart-musculature. 
 
2.5.2 Endosymbiotic Theory 
The endosymbiotic theory was founded by Konstantin Mereschkowsky at the beginning of 
the 20th century and is based on the assumption that mitochondria used to be individual 
(aerobe) organisms that migrated into (anaerobe) host cells to live in a symbiosis 
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(Mereschkowsky K. 1910, Margulis L. 2004). The term “endosymbiosis” origins from the 
Greek words “endo” – inside and “symbiosis” – living together. 
Closer inspection of mitochondria shows significant differences to other cell organelles and 
similarities to bacteria. Mitochondria are organized into 2 membranes, which differ in their 
structural composition – the inner membrane is rich in cardiolipin. This lipid is almost only 
found in the inner membrane of mitochondria (Pangborn M.C. 1942, Horn F. 2002). They 
proliferate independently by division and contain their own circular mitochondrial DNA (mt-
DNA). Furthermore, the mitochondrial ribosomes enclose 70S and 30S subunits in 
contrast to eukaryotic ribosomes (Horn F. et al. 2002, Rassow J. et al. 2006). 
Differencesx in structure, mt-DNA and mt-ribosomes and proliferation, support the theory 
of prokaryotes taken inside other cells and developing a symbiotic lifestyle (Horn F. et al. 
2002, Martin W. et al 2012, Zimorski et al. 2014). 
 
2.5.3 Histology and structure 
Mitochondria are small, oval, vermicular cell organelles and occur in most eukaryotic 
organisms (Henze K. et al. 2003). They can be discriminated by their appearance into two 
groups: the cristae-type and the tubulus-type (Luft R. et al. 1962, Frey T.G. et al. 2000, 
Lüllmann-Rauch R. et al. 2006). The inner membrane is compartmentalized into a large 
number of lamellae or tubes to expand and enlarge the surface, which in due course 
increases the ATP production. Cristae-type mitochondria are found for example in renal 
cells, tubulus-type mitochondria are only found in steroid-hormone-producing cells 
(Lüllmann-Rauch et al. 2006, Rassow et al. 2006). 
The organelles are composed of two membranes that separate them into two different 
compartments. The outer membrane – a phospholipid bilayer – contains several so called 
porins that facilitate the diffusion for proteins <5000kDa. Furthermore, the outer membrane 
contains translocase of the outer membrane (TOM), a protein-complex that allows and 
helps transporting proteins into the intermembrane space (Fleischer et al. 1967, Horn et 
al. 2002, Rassow et al. 2006, Herrmann et al. 2000). 
The inner membrane is rich in Cardiolipin a lot less permeable for molecules, it contains a 
large variety of transport mechanisms - for example the translocase of the inner membrane 
(TIM), the Pyruvate-translocator, the ADP/ATP-translocator, Ca2+-Na or H-antiporter - to 
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enable protein-exchange and metabolic pathways. Moreover, the inner membrane 
contains the respiratory chain and the ATP-Synthase (Bernardi P. 1999, Rassow J. et al. 
2006, Horn F. et al. 2002). 
The Pyruvate-Dehydrogenase-Complex is located in the mitochondrial matrix, as well as 
the beta-oxidation and the Krebs-Cycle. In addition, parts of the Heme-Biosynthesis and 
the Urea-Cycle take place in the matrix, which is an important Ca2+-store (Bernardi P. 1999, 
Rassow J. et al. 2006, Horn et al. 2002). Further, it contains mitochondrial DNA (mDNA), 
a circular plasmid which stores genes for mitochondrial proteins (Rassow J. et al. 2006, 
Horn F. et al. 2002). 
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2.5.4 Reproduction and inheritance 
Mitochondria are capable of reproduction via growing and developing septa that lead to 
separating the organelle into 2. The average lifespan of a mitochondrion is approximately 
10-20 days, afterwards they are degraded in the lysosomes. Due to the maternal 
inheritance of mitochondria, defects and diseases are only passed along in the female line 
(Giles R.E. et al. 1980, Yaffe M.P. 1999, Sutovsky P. et al. 2000, Horn F. et al. 2002, 
Rassow J. et al. 2006).  
 
2.5.5 Mitochondrial Functions and Pathways 
The mitochondrion plays a very important role in the cellular metabolism and energy gain. 
Several metabolic pathways take – partly or fully – place in the mitochondrion and supply 
the electron chain with substrates to generate the needed amount of ATP. 
Figure 9 - Schematic image of a mitochondrion 
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Figure 10 - Schematic image of mitochondrial pathways and interactions 
 
Ingested carbohydrates are split by amylases in the small intestine, glucose-blood-levels 
are increasing, and glucose is transported into the pancreatic beta-cells. As a result, 
glucose is metabolized by glycolysis to ATP, the increased intracellular ATP levels lead to 
an inhibition of potassium efflux and following the cell depolarizes. This conducts an 
activation of voltage-dependent Calcium-channels which induce an exocytosis of insulin-
filled vesicles (Horn F. et al. 2002, Rassow J. et al. 2006). 
The binding of Insulin to the Insulin-receptor effectuates an increased glucose-uptake and 
–storage, and in its course, decreases the blood-glucose-values. Once inside the cell, 
glucose is – as mentioned previously – metabolized via glycolysis, the gained pyruvate is 
transported into the mitochondria, channeled into the Krebs-cycle, and further on to the 
electron chain. Glucose oxidation delivers approximately 36 ATPs per molecule glucose 
instead of 2 ATPs via glycolysis only (Horn F. et al. 2002, Rassow J. et al. 2006). 
However, the mitochondrion not only is the "power station of the cell". Parts of the steroid-
hormone-biosynthesis, reactive oxygen species production, regulation of apoptosis and 
calcium-homeostasis also take place in the mitochondria. The large variety of functions 
and metabolic interactions show the importance of mitochondrial integrity within the cells. 
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Alterations, mutations or damage can lead to major dysfunctions not only at a cellular level 
but can also can be a threat for a whole organism (Horn F. et al. 2002, Rassow J. et al. 
2006). 
 
2.5.5.1 Krebs Cycle 
The Krebs-Cycle is a pathway consisting of several reaction steps to utilize Acetyl-CoA 
and generate FADH2, which is channeled into the respiratory chain and further disposed 
to gain ATP. The Krebs-Cycle is an ongoing reaction cascade which is fueled by pyruvate, 
Acetyl-CoA and amino-acids. In addition to these substrates, this pathway also reuses 
reaction products such as NAD+, FAD, and H2O provided by the respiratory chain, the 
protein catabolism or other metabolism channels (Horn F. et al. 2002, Rassow J. et al. 
2006). 
Also, the Krebs-Cycle and its products are involved in a lot of further metabolic pathways: 
The transformation of Oxaloacetate to Aspartate or α–Ketoglutarate to Glutamate provides 
substrates for the amino-acid-biosynthesis. The condensation of Oxaloacetate with Acetyl-
CoA forms Citrate, this product is transported to the cytosol to be divided back to Acetyl-
CoA which is channeled to the Fatty-Acid-Biosynthesis and Oxaloacetate which is 
transported back into the mitochondrion. Succinyl-CoA is used as substrate for the 
Porphyrin-Biosynthesis, Malate in the gluconeogenesis (Horn F. et al. 2002, Rassow J. et 
al. 2006). 
 
Table 6 – energy efficiency of Krebs-Cycle  
FADH2 1 App. 1.5 ATP 
NADH 3 App. 7.5 ATP 
GTP 1 App. 1 ATP 
 
Total ATP = 10 
 
2.3.5.2 Beta-Oxidation 
The beta-oxidation serves as a catabolic pathway to reduce fatty acids and generate 
Acetyl-CoA. The gained molecule is channeled into the Krebs-Cycle and metabolized to 
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NADH, FADH2 which are further used for the production of ATP through the respiratory 
chain.  
The beta-oxidation itself takes place in the mitochondrial matrix, to start a reaction the 
substrate Acyl-CoA has to be transported into the Mitochondria. In the cytosol, free fatty 
acids bind to coenzyme A and forms Acyl-CoA, which then binds to the transporter 
Carnitine and is transported into the mitochondrial matrix (Horn F. et al. 2002, Rassow J. 
et al. 2006). 
The energy efficiency of one beta-oxidation cycle is approximately 14 ATP. 
 
Table 7 – energy efficiency of Beta-Oxidation 
FADH2 1 App. 1.5 ATP 
NADH 1 App. 2.5 ATP 
AcetylCoA 1 App. 10 ATP 
 
Total ATP = 14 
 
2.3.5.3 Pyruvate-Dehydrogenase-Complex 
The Pyruvate-Dehydrogenase-Complex, a multi-enzyme-complex situated in the 
mitochondrial matrix. By catalyzing Pyruvate to Acetyl-CoA, PDH-Complex it links the 
depletion of glucose (Glycolysis) to and provides substrates for the Krebs-Cycle and 
further supplies the electron chain to gain ATP. 
The regulation of the Pyruvate-Dehydrogenase-Complex functions via product regression 
– sufficient amounts of Acetyl-CoA in the mitochondrion effectuate a reversible 
phosphorylation via a Kinase and in its course the PDH is inhibited. As soon as the Acetyl-
CoA amounts decrease, a phosphatase is activated and separates the phosphate-rest 
from the enzyme-complex. By this separation the inhibition is reversed, and the enzyme-
complex is active again (Horn F. et al. 2002, Rassow J. et al. 2006). 
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2.5.5.4 Respiratory Chain 
 
Figure 11 - graphical illustration of the respiratory chain 
 
Electron chain (also called respiratory chain) is situated in the inner mitochondrial 
membrane and composed of four interacting complexes. Different metabolic pathways 
channel their reaction products and generated electrons into the electron chain, then they 
are then used for a cascade of redox-reactions to create a proton-gradient. This proton-
gradient is needed to power the ATP-Synthase-Complex, an enzyme-complex which 
synthesizes ATP from ADP and Pi. 
Complex-I (NADH-Dehydrogenase) accepts electrons donated from NADH-molecules 
from various catabolic pathways. Using four electrons Ubichinon is further reduced to 
Ubihydrochinon and 4 additional electrons can be transported to the inter-membrane-
space (Horn F. et al. 2002, Rassow J. et al. 2006). 
The connection between respiratory chain and Krebs-cycle is the enzyme Succinate-
Dehydrogenase. It is a citric-acid-cycle enzyme and at the same time Complex-II of the 
electron chain. Here Succinate is transformed to Fumarate, while reducing FAD to FADH2 
and Ubichinon is reduced to Ubihydrochinon (Horn F. et al. 2002, Rassow J. et al. 2006). 
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Complex-III, the Cytochrome-C-Reductase is responsible for regenerating the reduced 
Ubichinon-molecules via the q-cycle, a reaction cascade that finally transfers two electrons 
onto Cytochrome-C and two electrons are transported back into the inter-membrane-space 
(Horn F. et al. 2002, Rassow J. et al. 2006). 
The last step, Complex-IV, the Cytochrome-C-Oxidase, is responsible for oxidizing the 
electron-loaded Cytochrome-C-molecules. Transmitting 2 electrons onto oxygen is a 
highly exergonic reaction step, H2O emerges (Horn F. et al. 2002, Rassow J. et al. 2006). 
The reaction cascade and its individual reaction steps generate – as mentioned previously 
– a proton-gradient that is necessary to synthesize ATP. This glucose oxidation is a highly 
efficient way to utilize pyruvate and Acetyl-CoA and generate a significantly higher amount 
of energy (Horn F. et al. 2002, Rassow J. et al. 2006). In addition, a sufficient capacity of 
glucose oxidation or mitochondrial respiration facilitates the manufacturing of reactive 
oxygen species, necessary for the apoptotic behavior and pathway within the cell (Feng J. 
et al. 2001). 
 
2.5.6 Mitochondrial diseases 
These mainly pediatric or neurologic disorders are clinical pictures caused by a dysfunction 
or alteration in mitochondria. Due to the key role of mitochondria in energy gain, many 
patients show symptoms such as weakness, muscle weakness, fading muscle-control and 
neurological deficiencies, limited exercise capacity, heart- lung- liver- and kidney-disease, 
hearing- or vision-loss, cognitive deficits, or short stature. 
Examples for mitochondrial diseases (taken from Dimauro S. et al. 2005): 
“LHON – Leber's Hereditary Optic Neuropathy” 
“Leigh-Syndrome” 
“MERRF - Myoclonic Epilepsy with Ragged Red Fibers” 
“MELAS - Mitochondrial myopathy, Encephalomyopathy, Lactic Acidosis, Stroke-like 
symptoms” 
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2.5.7 Mitochondria in cancer 
The mitochondrion holds and important key function in the cellular metabolism. It handles 
pyruvate by channeling it into the Krebs-Cycle and therefore fueling the respiratory chain 
to generate ATP. The aerobic glucose-utilization is a very sufficient and highly developed 
but complex pathway and not only provides energy but also produces reactive oxygen 
species (ROS). Every developed and complex system is also prone to error. In case of 
mitochondria, alterations in biochemical and metabolic pathways or enzyme organization 
can result in lowered capacity for respiratory control (Luft R. et al. 1962), changed behavior 
and resistance to apoptosis (Bonnet S. et al. 2007). 
In 2002 Carew J.S. et al. suspected that reduced apoptosis rates in cancer cells and 
tumors could be explained by impaired function of the respiratory chain – down-regulated 
activation of mitochondria lead to decreased oxidative phosphorylation, this further results 
in less production of pro-apoptotic factors and decreased levels of apoptosis. In addition, 
in 2002 Carew J.S. et al. hypothesized that mitochondrial DNA mutations and changes in 
respiratory activity appear to be characteristics of cancer cells. 
The adequate function of the respiratory chain is essential to produce reactive oxygen 
species. A reduction in respiratory chain activation leads to a reduced ROS level, which 
can result in altered apoptotic behavior, aging processes and mutagenesis of mtDNA 
(Carew J.S. et al. 2002, Sandeep R. et al. 2006). 
Mitochondrial DNA alterations are found in several cancer types such as gynecological 
tumors (breast- and ovarian-cancer), gastrointestinal-tumors (esophageal-, gastric-, 
colorectal-cancer), malignant growth in liver and pancreas as well as renal-cell-cancer, 
prostate-cancer and brain-tumors (Carew J.S. et al. 2002, Thierbach R. et al. 2005).  
 
2.6 Warburg-Effect 
In 1924 Otto Warburg, a German physician and biochemist, and his team investigated the 
differences between healthy muscle tissue and carcinoma muscle tissue extracted from 
frogs. The investigation showed, that carcinoma cells had increased levels of lactate in 
relaxed and active state compared to healthy ones. The team also proved a correlation 
between elevated glycolysis rates at higher pH levels (Warburg O. et al 1924). Further 
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investigations in animal models and tests with human cancer cells showed a shift from 
respiration to fermentation energy. It was suspected that either an irreversible injury of 
respiration had occurred, or the coupling of respiration and ATP formation was damaged 
(Lynen F. 1942, Warburg O. 1956). 
Oxidative use of glucose is a more effectively way to generate ATP in the presence of high 
oxygen levels than generating ATP via anaerobic glycolysis; however, Warburg’s’ 
investigations showed a transition of metabolism and energy gain in cancer cells. 
Increased glycolysis in cancer cells leads to the assumption that the mitochondrial function 
could be impaired and explain the metabolic shift. Further investigations showed altered 
mitochondrial function, affected glucose oxidation as well as elevated glycolysis and 
lactate rates. Also decreased oxidative capacity (and less ROS production) could lead to 
apoptosis resistance. The conclusion was that reduced Krebs-cycle, decreased 
mitochondrial function and hampered apoptosis could promote cancer (Cuezva J.M. et al. 
2002, Thierbach R. et al. 2005, Schulz T.J. et al. 2006). 
The Warburg-Effect has never been distinctly confirmed, although recent studies report a 
connection between metabolic and genetic changes observed during malignant growth. 
 
Considering the Warburg-Theory, a line to the changed behavior seen in IPAH such as 
resistance to apoptosis, changes behavior in proliferation and transition from glucose 
oxidation towards anaerobic glycolysis (Sutendra G. et al. 2014). 
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3. Hypothesis, aims and goals 
Suppression of mitochondrial bioenergetics are associated with abnormal pericyte 
behavior and impaired angiogenesis in PAH. 
 
3.1 Exploring the Hypothesis 
To explore significant changes in IPAH pericytes compared to healthy ones, we extracted 
this particular cell type from healthy and diseased lung tissue and cultured them in pericyte 
full media, until 100% confluency was reached. The cells were lysated, collected and 
prepared for the microarray. The microarray was conducted with the Ambion Illumina RNA 
amplification kit and the slides were analyzed by using BeadStudio (Illumina, Inc). The 
gained raw data was analyzed using GeneSpring. 
Results: The analyzed data showed an up-regulation of PDK-4 by 6.92-fold. 
The high up-regulation of PDK-4 led us to further investigations and provided an incentive 
for us to choose this enzyme as our goal of research. 
 
3.1.1 Pyruvate-Dehydrogenase-Kinase-4 
The enzyme pyruvate-dehydrogenase-kinase-4 (PDK4) is located in the mitochondrial 
matrix and in mammalians it is mainly found in skeletal- and heart-muscle (Pilegaard H. et 
al. 2004). It consists of 411 amino acids and has a molecular weight of approximately 
46kDa.  
The PDK-4 inhibits the Pyruvate-Dehydrogenase-Complex via phosphorylation, therefore 
the pyruvate shift and thus the substrate flow into the mitochondria is blocked (Rowles J. 
et al. 1996, Sugden M.C. et al. 2006). By decreasing or blocking the fueling of Krebs-cycle 
and respiratory chain, the manufacturing of ATP and reactive oxygen species (ROS) 
cannot take place. A lack of ROS can lead to a higher resistance to apoptosis or altered 
apoptotic behavior. Furthermore, the lack of ATP must be counterbalanced by activating 
anaerobe glycolysis and causes increased intracellular lactate levels. This elevated lactate 
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generation - as a result of diminished glucose oxidation in the respiratory chain - is often 
seen in malignant cells and tumors (McFate T. et al. 2008). Also, an elevation of the PDK-
4 gene is associated with other diseases, for example pulmonary arterial hypertension, 
rectal prolapse and non-insulin dependent Diabetes Mellitus (Jeoung N.H. et al. 2008; Piao 
L. et al. 2013, Deol P. et al. 2015). 
The PDK-4 gene expression depends on a large variety of surrounding conditions. 
Increased levels of PDK-4 expression are found during fasting or exercise - short term high 
and prolonged low-intensity exercise – as well as catabolic conditions. In addition, the 
expression is also regulated via glucocorticoids, retinoic acid and insulin. Glucocorticoids 
and retinoic acid enhance PDK-4 whereas increased levels of insulin inhibit the expression 
of PDK-4 (Wu P. et al. 1998, Huang B. et al. 2002, Pilegaard H. et al. 2004, Kwon H.S. et 
al. 2006, Connaughton S. et al. 2010).  
 
3.2 Aim 1: Investigating PDK-4 regulation 
Is PDK-4 up-regulated in IPAH-pericytes compared to healthy pericytes? 
To measure the PDK-4 expression in healthy and sick IPAH pericytes, we cultured cells of 
both tissues in full media and seeded them on Collagen I plates (10µg/ml). We conducted 
an RNA-extraction with an RNeasy-Mini-Kit, measured the gained RNA with 
NanoDrop2000 and converted it into c-DNA. A q-PCR was conducted with TaqMan. 
Results: The q-PCR showed a significantly up-regulated PDK-4 activation by 3.46-Fold-
change. 
To verify our q-PCR results we did 2 Western-Blots, neither of them showed a significant 
band for the PDK-4 antibody, however we tested the Anti-PDK-4-Antibody Human-Heart-
Lysate and got a strong band in blot 2. 
Although none of the western blots showed any significant result, we decided to further 
investigate PDK-4 as possible cause of different behavior in IPAH pericytes. To verify 
changes in apoptosis, proliferation, migration and metabolism we started experiments 
targeting these actions. 
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3.3 Aim 2: Investigating Metabolic Alterations 
Does PDK-4 up-regulation cause further changes in cell metabolism? Can we prove our 
assumption, that PDK-4 up-regulation inhibits the PDH-complex and in its course, 
decreases the pyruvate shift into mitochondria? The lack of substrate will shut down the 
Krebs-Cycle and electron chain – can we show change in membrane potential and a 
decrease in ROS production? 
  
Measuring Mitochondrial Transmembrane Potential (∆Ψm) with TMRE in WT- and IPAH 
pericytes: 
Cell cultures of Healthy- and IPAH-pericytes had been cultivated and treated with TMRE 
(tetramethylrhodamine ethyl ester) to label the membrane potential in mitochondria 
(Invitrogen/Molecular Probes) and PDK-4 to visualize the amount in healthy and sick cells. 
Furthermore, the stained pericytes were analyzed with an immunofluorescence 
microscope and the analyzing program Image J. 
Results: The mean CFTF for TMRE was elevated ca. 28% in IPAH pericytes compared to 
WT pericytes. The mean CFTF for PDK-4 was elevated approx. 50% in IPAH pericytes 
compared to WT pericytes. 
 
Measuring ROS-activity in WT-pericytes and IPAH-pericytes 
WT- and IPAH-pericytes had been cultivated in full-pericytes-media and then treated with 
CellROX-Reagent (Molecular Probes by life technology) to explore the possible alterations 
in reactive oxygen species production in sick cells. After staining the cells with the dye, the 
pericytes were analyzed with an immunofluorescence microscope and the analyzing 
program Image J. 
Results: The mean CFTF for CellROX-Reagent was decreased ca. 42.9% in IPAH-
pericytes compared to WT-pericytes. 
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3.4 Aim 3: Further Investigations 
With our previous experiments we have already shown the changes in metabolism at 
highly elevated PDK-4 levels. DCA as PDK-inhibitor should reverse the observed 
alterations in cell metabolism. Which experiments would give use proof of this assumption? 
Dichloroacetate is a small molecule inhibiting PDK-isoenzymes and therefore releasing 
the inhibition of PDH-complex previously done by PDK. Several studies and clinical trials 
using DCA as an inverter of the effects on the metabolism of PDH-complex inhibition have 
been done. 
 
3.3.4 Future Attempts  
DCA-treatment of IPAH-pericytes compared to non-treated IPAH-pericytes and WT-cells: 
We suspect that altered behavior of IPAH-pericytes in migration, apoptosis and 
proliferation is a result of a PDK-4 up-regulation and therefore an inhibition of the PDH-
Complex. With an inhibited substrate flow into the mitochondria, the activation decreases 
and with it the ATP- and ROS-production. DCA as PDK-inhibitor should reverse those 
effects. 
Can we visualize the supposed impact of DCA on IPAH-pericytes by treating cultivated 
IPAH-cells with DCA and comparing them to an IPAH-reference plate and a WT-pericytes 
plate? If this DCA-hypothesis proved true, we would see cell-networks on the IPAH-plate 
similar to healthy cells. 
 
Measuring ∆Ψm after treating IPAH-Pericytes with DCA: 
We have already shown the difference between ∆Ψm in WT- and IPAH-pericytes. Would 
it be possible to demonstrate the mitochondria-activating effects of DCA in IPAH-pericytes, 
if we – hypothetically speaking – treated one IPAH-pericytes group with a certain 
concentration of DCA, then stained this group with TMRE, measured the CFTF and 
compared the gained value to the baseline-value of an untreated IPAH-pericytes group? 
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Theoretically speaking, the ∆Ψm of DCA-treated sick cells should be revised to 
(depolarized) normal values. 
 
Measuring reactive oxygen species production after treating IPAH-Pericytes with DCA: 
In one of our experiments we showed the transformation of reactive oxygen species 
production in IPAH pericytes. We could prove a significant decrease in CellROX-CFTF 
IPAH-pericytes compared to WT-pericytes. 
If we compiled a similar hypothesis to the TMRE-experiment – treating IPAH pericytes with 
DCA, later measuring the ROS-production and comparing the gained data to a baseline 
value of non-treated IPAH-pericytes – could we also prove a difference? 
If DCA activated the mitochondria via inhibiting PDK-4 and indirectly activating the PDH-
complex, sufficient substrate flow should be regained. With an abundant flow of fuel into 
the Krebs-Cycle and the electron chain, the ROS-production should increase significantly. 
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4. Material and Methods 
4.1 Used cell types 
Lonza: vascular smooth muscle cells 
Sciencell: vascular smooth muscle cells 
ST0: iPAH pericytes 
CC0: iPAH pericytes 
 
4.2 Media for Pericytes 
The used media for pericytes contained fetal bovine serum, pericytes growths 
supplements and penicillin/streptomycin solution. 
 
4.3 Cultivation and Growth of Pericytes 
Liquid full media plates were incubated at 37°C, overnight. The pericytes-full-media was 
changed every two to three days, after the plates had reached 100% confluency; the cells 
were washed with PBS, treated with 2ml Trypsin and incubated at 37C for one minute. 
Afterwards the cells were washed off the plate with full media and collected in a 10ml tube. 
The fluid was centrifuged for 5min with a speed of 400rpm at 25°C, the protrusion was 
abolished. The remaining pellet was resuspended with 5ml full media and the liquid was 
separated onto 5 plates, 1ml per plate, filled up with 9ml of full fresh media each. 
 
4.4 RNA-Extraction with Rneasy Mini Kit (EN-Rneasy 
Mini Handbook, QUAIGEN, 2010) 
The pericytes were grown on fluid 10ml-full-media plates, incubated at 37°C. When they 
reached 100% confluency, the plate was washed with PBS twice and afterwards the cells 
were lysated with 600 µl of lysate buffer. The lysatebuffer contained 10µl beta-
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Mercaptoethanol in 1ml RTL-Buffer. The cells were scratched off the plate and pipetted 
into a 2ml tube, homogenized with a 5ml syringe and a 0.9mm needle 10 times, then the 
same volume of 70% ethanol was added to the solution and mixed well. 
700µl were transferred to a RNeasy-Mini-spin-column (placed in a 2ml collection tube), 
and spinned for 15 seconds at ≥ 8000 x g. After spinning, the fluid was abolished, another 
700µl were added to the tube and centrifuged again for 15s at ≥ 8000 x g. The fluid was 
abolished, 500µl of RPE-Buffer were added to the tube and spinned for 15s at ≥ 8000 x g 
again. Another 500µl RPE-Buffer were added and spinned for 2min at≥ 8000 x g. The 
column was placed in a new collection tube (1.5ml), 50µl of RNase-free water were added 
and spinned for 1min at ≥ 8000 x g. The collected RNA was measured and stored at -
80°C. 
 
4.5 RNA-Measurement with NanoDrop 2000 
For measuring the RNA concentration, the NanoDrop2000 with a wavelength of 190-
840nm and a concentration range of 0.4-15,000ng/µl was used. The tool was blanked with 
RNAse-free water first, afterwards each sample was mixed gently and 0.5µl were pipetted 
on the measuring surface. Between each sample the surface was cleaned carefully. 
The NanoDrop2000 software measured the RNA concentration; it was marked on the 
samples itself and filed on the computer. The samples were stored at -80°C. 
 
4.6 Gene-Expression Measurement with Microarray 
RNA labeling and microarray hybridization – using an Illumina HumanHT-12_v4_Beadchip  
Staring material: 250ng of total RNA. 
 
Each RNA sample was amplified using the Ambion Illumina RNA amplification kit with 
biotin UTP labeling. The Ambion Illumina RNA amplification kit uses T7 oligo(dT) primer 
to generate single stranded cDNA followed by a second strand synthesis to generate 
double-stranded cDNA, which is then column purified. In vitro transcription was done to 
synthesize biotin-labeled cRNA using T7 RNA polymerase. The cRNA was then column 
purified. The cRNA was then measured and total of 750 ng of cRNA was hybridized for 
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each array using standard Illumina protocols with streptavidin-Cy3 being used for 
detection. Slides were scanned on an Illumina Beadstation and analyzed using 
BeadStudio (Illumina, Inc). 
 
4.7 Analyzing the Data with GeneSpring 
The GeneSpring software (Agilent, Santa Clara, CA) was used for statistical analysis and 
normalization of microarray data. Raw array data (.txt) files were uploaded to GeneSpring 
and it was analyzed using the GeneSpring Advanced Workflow.  
The raw data of WT-pericytes was compared to the raw data of IPAH-pericytes and 
analyzed with the Advanced-Workflow. Further a list of differentially regulated genes was 
created, a fold change of >2 was used as a cut off. The list was narrowed by choosing the 
10 highest up- and down-regulated genes and following sorted by fold change. To name 
a gene of interest, the most elevated fold change was used as marker. 
 
4.8 TaqMan q-PCR  
PDK-4 primer: TaqMan primer with unknown sequence. 
The collected RNA was turned into cDNA (Fermentas cDNA reaction) and a sample, 20µl 
with 50ng/µl was used for the following q-PCR. 
The q-PCR reaction was prepared with using the following formula: 
 
2X TaqMan PCR Master Mix 25µl 
20X FAM Primer 2.5µl 
Sample DNA 2µl 
H²O 20.5µl 
Total 50µl 
 
15µl from the total volume of 50µl were loaded onto the plate as triplicates, after the loading 
the plate was centrifuged for 1-2min with 1300rpm. The computer settings were done and 
the program was started for 1.5h. Afterwards the data was analyzed and exported. 
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4.9 Western Immunoblot 
The cells were washed three times with ice-cold 1xPBS, and lysates were prepared by 
adding boiling lysis buffer (1xRIPA and 1mM PMSF). The cells were scraped off the plate, 
pipetted into a 1.5-ml microcentrifuge tube, and boiled for 10 min before spinning.  
The resulted overlaps were pipetted to fresh microcentrifuge tubes and stored at -80° C. 
The protein concentration was measured by the Lowry assay (Bio-Rad Laboratories).  
A Bis-Tris-Gel (4-12%; Life Technologies, USA) was prepared and even amounts of 
protein were loaded onto each lane. Then the gel was exposed to SDS-Page 
electrophoresis under reducing conditions. 
Following PVDF membranes were blocked for 1h in blocking buffer (5% milk powder in 
0.1% PBS/Tween20) and afterwards incubated with primary antibodies for PDK-4 (rabbit 
antibody) and Human Heart Lysate (HHL) overnight at 4 °C. HRP conjugated secondary 
antibodies were visualized by ECL (Amersham, USA). Signal normalization was performed 
with a mouse monoclonal antibody against α-tubulin (Sigma-Aldrich, USA). 
 
4.10 Measuring mitochondrial membrane potential 
with TMRE (Invitrogen/Molecular Probes) 
Healthy and IPAH-pericytes were cultivated in full media. The preparations were done as 
described in the protocol and a staining solution with a concentration of 600nM TMRE in 
full media was prepared. 
The culture media was aspirated, the cells were immersed in 600nM TMRE at 37°C for 
10mins. Then the dyeing solution was removed and the cells were washed once with PBS. 
For fixation, the cells were treated with formaldehyde (4%) for 10mins at room-
temperature. Following the formaldehyde was removed, the plates were washed one time 
with PBS, and then the cells were covered with fresh PBS and stored at 4°C. 
The cells were imaged by an immunofluorescence microscope (λ-excitation 548 nm; λ-
emission 573 nm), pictures were taken and later analyzed by Image J. 
[Used Protocol, changes were made (see above): Labelling Mitochondria with TMRM or 
TMRE by Brad Chazotte; Cold Spring Harb. Protoc; 2011; doi:10.1101/pdb.prot5641]. 
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4.11 Measuring ROS-Production with CellROX 
(Molecular Probes by life technology) 
Healthy and IPAH-pericytes were cultivated in full media. The preparations were done as 
described in the protocol and a staining solution with a concentration of 5µM ROX reagent 
(Green reagent) in warmed full media was prepared. 
The cells were washed once with PBS, 250µl staining solution was pipetted on each well 
and incubated for 10mins at 37°C. After staining dyeing solution was removed and the 
cells were washed once with PBS. To fixate the cells, they were immersed in formaldehyde 
(4%) for 10mins at room temperature. Then the formaldehyde was removed, the cells 
washed with PBS and following covered with fresh PBS and stored at 4°C. The cells were 
imaged by an immunofluorescence microscope (λ-excitation ≈ 500 nm; λ-emission ≈ 530 
nm), pictures were taken and later analyzed by Image J. 
[Used Protocol, changes were made (see above): CellROX Oxidative Stress Reagents 
(Catalog nos. C10422, C10443, C10444, C10448); CellROX Green Reagent C10444 
molecular probes by life technologies]. 
 
 
  
 49 
 
5. Results 
 
5.1 Analyzing Microarray with GeneSpring  
 
Figure 12 - Microarray data 
(A) Microarray Data analyzed with GeneSpring, list of top 10 up- and down-regulated Genes. The Genes 
were filtered by fold change, a t-test was not done. 
(B) Diagram of microarray data analyzed with GeneSpring, filtered by fold change. The gene expression of 
IPAH pericytes and healthy cells were compared by a microarray and the raw data was analyzed by 
GeneSpring. PDK-4 showed the highest regulation in IPAH pericytes, compared to healthy ones it was up-
regulated with a fold change of 6.92. 
 
To analyze the gained Microarray data, we used the GeneSpring software (Agilent, Santa 
Clara, CA). The Microarray provided raw data (.txt) files, which was uploaded in and 
analyzed by GeneSpring (Advanced Workflow, fold change of >2 was used as cut off). By 
comparing the gene expression in WT-pericytes with IPAH-pericytes, the analysis 
procured a list of up- and down-regulated genes, which was narrowed down by choosing 
the 10 most elevated up- and down-regulations using the particular fold change.  
PDK-4 showed the highest peak in fold change overall with an up-regulation by 6.92-fold. 
We chose PDK-4 as our gene of interest and started further investigations. 
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5.2 TaqMan q-PCR 
 
Figure 13 – TaqMan q-PCR 
(A) - Experimental results for TaqMan qPCR comparing healthy and IPAH pericytes. The control gene 18s 
was chosen for its consistent gene expression over time. The data shows that the gene PDK4 was 
expressed significantly more in IPAH pericytes, since it took a lower number of cycles to reach the 
threshold.  
(B) -The fold change Increase was calculated by subtracting the CTRL gene expression cycle number 
from the PDK4 value and for both Healthy and IPAH pericytes. These values were subtracted from each 
other, and the result inserted in following formula: Relative fold change increase=2^x 
The data showed a significantly up-regulation of PDK-4 in IPAH pericytes and underlined our previously 
gained data 
 
(A - Experimental results for TaqMan qPCR comparing healthy and IPAH pericytes. The 
control gene 18s was chosen for its consistent gene expression over time. The data shows 
that the gene PDK4 was expressed significantly more in IPAH pericytes, since it took a 
lower number of cycles to reach the threshold. 
B -The fold change Increase was calculated by subtracting the CTRL gene expression 
cycle number from the PDK4 value and for both Healthy and IPAH pericytes. These 
values were subtracted from each other and the result inserted in following formula: 
Relative fold change increase=2^x 
The data showed a significantly up-regulation of PDK-4 in IPAH pericytes and underlined 
our previously gained data.) 
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To verify our gained Microarrays data – a highly up-regulated PDK-4 in IPAH pericytes in 
comparison to healthy cells - we performed a TaqMan q-PCR with a PDK-4 (TaqMan) 
primer of unknown sequence. The q-PCR was done and showed an up-regulation of PDK-
4 by 3.46-fold. These results strongly supported our GeneSpring data and led to further 
investigation. 
 
5.3 Western-Immunoblot  
 
Figure 14 – Western Immunoblot 
(A) – experimental results for Western-Immunoblot with PDK-4 Antibody and Human Heart Lysate (HHL). 
The specific weight for PDK-4 Antibody as well as for HHL is 46kDa. As expected the Human Heart Lysate 
(HHL) is clearly visible 46kDa. However, we expected there to be a significant band for PDK-4 Antibody at 
46kDa in healthy pericytes (P) and IPAH pericytes (IP). WesternBlots are known to be more effective in 
detecting proteins rather than enzymes, this could be an explanation for the lack of significant bands for 
PDK-4. 
(B) – The graphical analysis of the Western-Immunoblot using the program Image-J resulted in a minimal 
higher relative intensity of PDK-4 in IP (IPAH pericytes) compared t healthy pericytes. The result is not 
significant, therefore a statement cannot be made 
 
As verification for the TaqMan q-PCR data, 2 Western-Immunoblots were done, using 
PDK-4 Antibody (rabbit antibody), Human Heart Lysate (HHL) and Tubulin as control. 
Neither of the blots showed a distinct band for PDK-4, but HHL showed a significant and 
strong band at 46 and 62kDa as well as Tubulin at 49kDa. 
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5.4 Measuring Mitochondrial Transmembrane 
Potential with TMRE in WT- and IPAH pericytes  
 
Figure 15 –Staining WT- and IPAH-pericytes with TMRE and PDK-4.  
Staining IPAH- and WT-pericytes with TMRE, the IPAH-cells show a 28% increased value. Staining with 
PDK-4 reveals a 50% elevation in IPAH cells compared to WT-cells 
 
To visualize the changes in mitochondrial membrane potential we stained WT- and IPAH-
pericytes with TMRE at a concentration of 600nM for 10mins. To image the cells an 
immunofluorescence microscope was used (λ-excitation 548 nm; λ-emission 573 nm). The 
pictures were analyzed with Image J. using a Histogram. The fluorescence was measured 
and the mean CFTF (Corrected total cell fluorescence = Integrated Density – (Area of 
selected cell X Mean fluorescence of background readings)) was calculated. 
 
The mean CFTF for TMRE was ca. 28% elevated in IPAH pericytes compared to WT 
pericytes. The mean CFTF for PDK-4 was approx. 50% elevated in IPAH pericytes 
compared to WT pericytes. 
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5.5 Measuring ROS production  
 
Figure 16 - Measuring ROS-production in IPAH- and WT-pericytes 
Both, PAH- and WT-pericytes were stained with CellRox to visualize the ROS production and possible 
changes. After staining and imaging, the CFTF was calculated and showed a 42.9% decrease of ROS in 
IPAH-pericytes compared to WT-pericytes. (Corrected total cell fluorescence = Integrated Density – (Area 
of selected cell X Mean fluorescence of background readings)). 
 
To visualize the changes in ROS production we stained WT- and IPAH-pericytes with 
CellRox at a concentration of 5µM for 10mins. To make a statement about ROS production 
in WT-pericytes and IPAH pericytes, we stained the cells with CellRox (green reagent) at 
a concentration of 5µM for 10mins. To evaluate the changes in ROS production in IPAH-
pericytes the gained data an immunofluorescence microscope (λ-excitation ≈ 500 nm; λ-
emission ≈ 530 nm) was used and pictures were taken for documentation. The images 
were uploaded into Image J, a histogram was made (measuring the fluorescence) and the 
gained data was analyzed. Again, the CFTF (Corrected total cell fluorescence = Integrated 
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Density – (Area of selected cell X Mean fluorescence of background readings)) was 
calculated. 
 
The mean CFTF showed an approx. 42.9% decrease of ROS in IPAH-pericytes compared 
to WT-pericytes.  
 
6. Discussion 
Our initial focus of research was to investigate the origins and underlining mechanisms 
that cause the observed pathologies idiopathic pulmonary arterial hypertension.  
We hypothesized that known macro- and microscopic alterations such as vessel-wall 
thickening and lumen narrowing could be caused by modified pericytes. As previously 
mentioned, increased proliferation of pericytes in IPAH lung tissue results in an elevated 
diameter of the vessel walls and subsequently increased intravascular pressure due to a 
higher resistance of the vessel wall (Lee S.D. et al. 1998). Therefore, our first goal was to 
explore the general differences of IPAH-pericytes compared to wild type pericytes. We 
started our investigation by extracting pericytes from idiopathic arterial hypertension lung 
tissue and healthy lung tissue following a MicroArray. The gained raw data was analyzed 
by using the GeneSpring software, the results showed an upregulation of PDK-4 by 6.92-
fold in IPAH-pericytes compares to WT-pericytes. This finding supported our hypothesis 
of significant changes in IPAH pericytes. The enzyme PDK-4 is a suppressor of the 
pyruvate-dehydrogenase-complex and effectuates the downregulation of substrate flow 
(pyruvate) into the mitochondrion. By doing so, the Krebs-cycle and the electron chain lack 
of fuel and following decrease their production of ATP via oxidative phosphorylation and 
reactive oxygen species (Rowles J. et al. 1996, Sugden M.C. et al. 2006). To confirm our 
results of the MicroArray analysis, we decided to conduct another investigation, proving a 
PDK-4 upregulation in IPAH pericytes. We performed a TaqMan q-PCR, the investigation 
showed a PDK-4 activation by 3.46-Fold. In addition to the qPCR experiments, we 
conducted two Western-Immunoblots using a PDK-4 antibody. Both experiments did not 
show any significant result. Considering the strong results of the MicroArray data, we 
decided to proceed our investigations of possible PDK-4 overexpression related alterations 
in IPAH, despite the disappointing Western-Blot experiments. Since these first results 
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supported our assumptions - that an overexpression of PDK-4 could explain the observed 
pathological changes in IPAH pericytes compared to the cellular behavior in migration, 
proliferation and apoptosis in wild type pericytes – we decided to research the metabolic 
behavior. Our focus turned to the investigation of the cellular metabolism. To specifically 
target the metabolic pathways, influenced by a PDK-4 overexpression, the mode of action 
of this enzyme must be understood.  
As previously mentioned, PDK-4 is responsible for the substrate flow into the 
mitochondrion. It inhibits the pyruvate-dehydrogenase-complex by phosphorylating a 
subunit. In a phosphorylated state, the PD-complex is no longer able to transform pyruvate 
to Acetyl-CoA and following Acetyl-CoA cannot be channeled into the Krebs-Cycle (Horn 
F. et al. 2002, Rassow J. et al. 2006). In a regular metabolic state, the Krebs-cycle is 
responsible for providing substrate for the respiratory chain and following facilitate 
oxidative phosphorylation. The ATP net balance undergoing oxidative phosphorylation is 
around 30 – 32 ATP per molecule glucose, compared to 2 ATP per molecule in anaerobe 
glycolysis (Rassow J. et al. 2006). In addition, the production of reactive oxygen species 
reduces under suppressed pyruvate-dehydrogenase-complex. Certain intracellular levels 
of ROS are important to maintain a normal apoptotic behavior in cells (Feng J. et al. 2001). 
Bonnet S. et al. (2007) showed that a depressed expression of potassium channels 
contributed to a higher resistance towards apoptosis and an inhibition of PDK indicated an 
increase in expression of potassium channels and reversed apoptotic behavior. 
Considering these information, a lack of ROS can lead to a higher resistance towards 
apoptosis and explain the findings in IPAH pericytes.  
To investigate this assumption, we executed two additional experiments, targeting the 
metabolism in IPAH pericytes compared to WT pericytes. By measuring the mitochondrial 
transmembrane potential, our investigation yielded a 28% elevation (of membrane 
potential) in IPAH pericytes compared to WT pericytes. These findings support the 
assumption, that increased membrane potential is a prohibitory factor for apoptosis. Vice 
versa a lowered membrane potential increases apoptosis rates (Bonnet S. et al. 2007). 
Further we stained PDK-4 in both investigated cell populations - the enzyme was 
approximately 50% elevated in IPAH pericytes. These results underline the findings of our 
first two experiments – an increased rate of PDK-4 in IPAH pericytes in comparison with 
WT pericytes.  
Our final trial targeted the fabrication of reactive oxygen species -  the attempt was to 
visualize the alterations in IPAH pericytes. Both cell samples were stained with a green 
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reagent and later evaluated with an immunofluorescence microscope. The investigation 
showed a decrease of ROS by approximately 42.9% in IPAH pericytes. Taking this 
reduction of the amount of reactive oxygen species in the analyzed disease cell sample in 
comparison with the healthy cell sample, it strongly supports our hypothesis of alterations 
in IPAH pericytes due to the observed PDK-4 overexpression.  
Summarizing our test series to investigate the possible origin of pathologies found in 
idiopathic pulmonary arterial hypertension, an overexpression of the enzyme pyruvate 
dehydrogenase kinase 4 explains the observed metabolic changes in IPAH pericytes. 
We hypothesized that an inhibition of the pyruvate dehydrogenase complex by PDK-4 
resulted in decreased activity of the respiratory chain and following diminished numbers of 
reactive oxygen species. In our investigations we proved a significant difference – a 
significant decrease – of reactive oxygen species in IPAH pericytes and therefore a 
lowered activity of the respiratory chain. Further we showed a significant distinction in 
membrane potential of wild type pericytes compared to IPAH pericytes. A higher 
membrane potential is associated with decreased values of apoptosis. 
Both investigations and their results gave a valid explanation of the observed raised 
resistance to apoptosis and following altered behavior in proliferation and migration in 
IPAH pericytes.  
Future investigations should concentrate on the effectiveness of PDK-4 and the reverse of 
its inhibition of the pyruvate dehydrogenase complex. By reversing this particular inhibition, 
a switch in metabolism from anaerobe glycolysis towards glucose oxidation, increase in 
ROS production, augmented expression of potassium channels and following decreased 
membrane potential could be achieved. Dichloroacetate - an inhibitor of PDK-isoenzymes 
- is already known and investigations concerning the potential have been researched in 
laboratory trials and clinical settings.  
Dichloroacetate (CHCl2COOH) is a small, mitochondria targeting molecule, and indirectly 
activates the PDH by inhibiting PDK-isoenzymes. The reagent only targets cells with a 
PKD-4 overexpression and inhibited PDH, by reversing the effects of PDK a big variety of 
metabolic pathways are enhanced (Kato M. et al. 2007, Michelakis E.D. 2008, Piao L. et 
al. 2013). Indirect activation of PDH leads to an increased transport of pyruvate into the 
mitochondria and substitutes the Krebs-cycle with fuel, which further invokes the electron 
chain and raises the amount of gained ATP (McAllister A. et al. 1973). An activated 
electron chain and sufficient supply with substrates such as pyruvate, not only increases 
the ATP gain but also the production of reactive oxygen species, which leads to higher 
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apoptosis rates (Bonnet S. et al. 2007, Tong J. et al. 2011). DCA inhibits several anabolic 
pathways such as gluconeogenesis, lipogenesis and cholesterol genesis; hence the 
peripheral glucose and lipid utilizations are increased. (Stacpoole P.W. 1989).  
DCA has already been used in clinical trials - Michelakis E.D. et al. published a study in 
2010, where the team showed – both in vitro and in vivo – significant changes in 
glioblastoma cells after treatment with DCA. The mitochondrial hypopolarization was 
reversed, the level of ROS as well as the levels of apoptosis were increased. The familiar 
side effects of DCA, such as a peripheral neuropathy were dose dependent and reversible. 
Other secondary effects did not occur. 
Further, positive effects of DCA given to patients with inherited mitochondrial diseases 
were proven. The patients not only showed significantly decreased levels of lactate and 
pyruvate, physical symptoms such as neurological disorders improved during therapy 
(DeStefano N. et al. 1995, Chinnery P. et al. 2006). Overall DCA is well tolerated in 
patients, possible side effects such as peripheral neuropathy have been shown as 
reversible (Stacpoole P.W. et al. 1998, Michelakis E.D. et al. 2010). 
Considering our results and the achievements gained by clinical trials using DCA as an 
inhibitor of PDK-isoenzymes, this substance has great potential for future investigations 
and experiments reversing the effects of metabolically changes due to PDK 
overexpression. 
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7.2 List of Abbreviations 
6MWD - 6-Minute-Walk-Distance 
ATP= Adenosine Triphosphate 
BMP-pathway - Bone Morphogenetic Protein Pathway 
BMPR2 - Bone morphogenetic protein receptor type II 
cAMP - Cyclic Adenosine Monophosphate 
CFTF – Corrected Total Cell Fluorescence 
cGMP - cyclic Guanosine Monophosphate 
CTEPH - Chronic thromboembolic pulmonary hypertension  
DNA - Deoxyribonucleic Acid 
ECG – Electrocardiogram 
FAD - Flavin Adenine Dinucleotide 
HHL - Human Heart Lysate 
IPAH - Idiopathic Pulmonary Arterial Hypertension 
kDa – kilo Dalton 
LHON – Leber's Hereditary Optic Neuropathy 
MELAS - Mitochondrial myopathy, Encephalomyopathy, Lactic Acidosis, Stroke-like 
symptoms 
MERRF - Myoclonic Epilepsy with Ragged Red Fibers 
mPAP – median Pulmonary Arterial Pressure 
mRAP – median Right Atrial Pressure 
mtDNA – mitochondrial Deoxyribonucleic Acid 
NAD - Nicotinamide Adenine Dinucleotide 
NYHA – New York Heart Association 
PAH - Pulmonary Arterial Hypertension 
PASP - Pulmonary Artery Systolic Pressure 
PDGFR-beta-1 - Beta-type Platelet-Derived Growth Factor Receptor 
PDK-4 - Pyruvate-Dehydrogenase-Kinase-4 
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PGH2 - Prostaglandin H2 
RAP – Right Atrial Pressure 
RNA - Ribonucleic Acid 
ROX - Reactive Oxygen Species 
sGC - soluble Guanylate Cyclase 
TAPSE- Tricuspid Annular Systolic Excursion 
TEE - Transesophageal Echo 
TGFbeta-1 - Transforming Growth Factor beta 1 
TIM - Translocase of the Inner Membrane 
TMRE - Tetramethylrhodamine Ethyl Ester 
TOM - Translocase of the Outer Membrane 
TRV - Tricuspid Regurgitant jet Velocity 
TTE – Transthoracic Echo 
VEGF - Vascular Endothelial Growth Factor 
VO2 – Qotient of Oxygen Uptake 
WHO – World Health Organization 
WT – Wild Type 
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